LCZ696 (Sacubitril/Valsartan)
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk ScoresJACC, 2015
- The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart FailureJACC, 2015
- Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart FailureCirculation, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Neprilysin Inhibition — A Novel Therapy for Heart FailureNew England Journal of Medicine, 2014
- The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trialEuropean Heart Journal, 2013
- Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studiesEuropean Heart Journal, 2012
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialThe Lancet, 2012